4.8 Review

When the Good Syndrome Goes Bad: A Systematic Literature Review

Journal

FRONTIERS IN IMMUNOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2021.679556

Keywords

Good syndrome; immunodeficiency; prognosis; clinical subgroups; infections

Categories

Ask authors/readers for more resources

Good syndrome, characterized by thymoma and hypogammaglobulinemia, is a rare adult-onset immunodeficiency. This study identified infection type and site as the main prognostic factors impacting survival of patients with Good syndrome. Cluster analysis revealed three clinical subgroups within Good syndrome with distinct characteristics and prognosis.
Background Good syndrome is a rare adult-onset immunodeficiency characterized by thymoma and hypogammaglobulinemia. Its clinical manifestations are highly heterogeneous, ranging from various infections to autoimmunity. Objective This study was to summarize patient characteristics, identify prognostic factors and define clinical subgroups of Good syndrome. Methods A systematic literature review was conducted to include patients with Good syndrome identified in PubMed, Embase and Cochrane databases between January 2010 and November 2020. Logistic and Cox regressions were used to identify prognostic factors impacting outcomes. Clinical subgroups were defined by multiple correspondence analysis and unsupervised hierarchical clustering. A decision tree was constructed to characterize the subgroup placement of cases. Results Of 162 patients included in the current study, the median age at diagnosis was 58 years and 51% were male. Type AB was the most common histological subtype of thymoma, and infections as well as concurrent autoimmune disorders were identified in 92.6% and 51.2% patients, respectively. Laboratory workup showed typical findings of combined immunodeficiency. Thymoma status (odds ratio [OR] 4.157, confidence interval [CI] 1.219-14.177, p = 0.023), infections related to cellular immunity defects (OR 3.324, 95% CI 1.100-10.046, p = 0.033), infections of sinopulmonary tract (OR 14.351, 95% CI 2.525-81.576, p = 0.003), central nerve system (OR 6.403, 95% CI 1.205-34.027, p = 0.029) as well as bloodstream (OR 6.917, 95% CI 1.519-31.505, p = 0.012) were independent prognostic factors. The 10-year overall survival was 53.7%. Cluster analysis revealed three clinical subgroups with distinct characteristics and prognosis (cluster 1, infections related to cellular immunity defects; cluster 2, infections related to other immunity defects; cluster 3, infections related to humoral and phagocytic immunity defects). A decision tree using infection types (related to humoral and cellular immunity defects) could place patients into corresponding clusters with an overall correct prediction of 72.2%. Conclusions Infection type and site were the main prognostic factors impacting survival of patients with Good syndrome. We identified three subgroups within Good syndrome associated with distinct clinical features, which may facilitate the study of underlying pathogenesis as well as development of targeted therapy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

What Are the Prospects for Treating TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia?

Chen Wang, David A. Sallman

Summary: TP53 is a crucial tumor suppressor gene frequently mutated in certain types of myelodysplastic syndromes and acute myeloid leukemia. Conventional treatments have limited effectiveness, but emerging targeted molecular and immunotherapies offer promise for this molecular subgroup. Unmet needs still exist for improving outcomes in TP53 mutated patients.

CANCER JOURNAL (2022)

Review Hematology

Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies

Chen Wang, David A. Sallman

Summary: Targeting the CD47/SIRPa axis in combination with other therapeutic agents shows promising treatment approach for patients with myeloid malignancies, especially the challenging TP53-mutated subgroup.

CURRENT OPINION IN HEMATOLOGY (2022)

Review Hematology

Autoantibodies in immunodeficiency syndromes: The Janus faces of immune dysregulation

Chen Wang, Jolan E. Walter

Summary: Immunodeficiency syndromes are a diverse group of genetic and acquired disorders characterized by various clinical manifestations. Autoantibodies, reflecting immune dysregulation, may contribute to certain clinical findings. The mechanism of autoantibody production in immunodeficiency is largely unknown, possibly influenced by genetic aberrations and infectious agents.

BLOOD REVIEWS (2022)

Review Immunology

What we have learned about lymphocytic variant hypereosinophilic syndrome: A systematic literature review

Yiyun Shi, Chen Wang

Summary: This study provides a comprehensive review of the clinical characteristics, treatment responses, and outcomes of lymphocytic variant hypereosinophilic syndrome (L-HES). The results show that L-HES patients have a heavier disease burden, and the presence of CD3(-)CD4(+) lymphocytes is associated with higher numbers of eosinophils and organ involvement. Corticosteroids are the most commonly used treatment, but additional therapies are often required. In addition, there is an increased risk of lymphoma transformation in L-HES patients, which may be associated with cardiovascular involvement and the use of imatinib.

CLINICAL IMMUNOLOGY (2022)

Meeting Abstract Hematology

Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

David A. Sallman, Hany Elmariah, Kendra Sweet, Asmita Mishra, Cheryl A. Cox, Marion Chakaith, Roshanak Semnani, Sheeba Shehzad, Asha Anderson, Helen Sabzevari, Amy Lankford, Onyee Chan, Luis SanchezMolina, Chen Wang, Eric Padron, Andrew Kuykendall, Rami S. Komrokji, Jeffrey E. Lancet, Marco L. Davila, Nelli Bejanyan

BLOOD (2022)

Meeting Abstract Hematology

Clinical Characterization and Outcomes of Patients with NPM1-Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

Chen Wang, Onyee Chan, Najla Al Ali, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman

BLOOD (2022)

Meeting Abstract Hematology

Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia

Somedeb Ball, Akriti G. Jain, Parth C. Patel, Chen Wang, Luis E. Aguirre, Mohammad O. Hussaini, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman

BLOOD (2022)

Meeting Abstract Hematology

Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency

Chen Wang, Bijun Sun, Kevin Wu, Jocelyn Farmer, Boglarka Ujhazi, Christoph B. Geier, Sumai Gordon, Emma Westermann-Clark, Sinisa Savic, Sargur Ravishankar, Karin Chen, Cullen M. Dutmer, Maria G. Kanariou, Mehdi Adeli, Paolo Palma, Carmem Bonfim, Evangelia Lycopoulou, Beata Wolska-Kusnierz, Dbaibo Ghassan, Jack Bleesing, Despina Moshous, Benedicte Neven, Catharina Schuetz, Geha Raif, Luigi D. Notarangelo, Maurizio Miano, David K. Buchbinder, Krisztian Csomos, Wenjie Wang, Ji-Yang Wang, Xiaochuan Wang, Jolan E. Walter

BLOOD (2022)

Meeting Abstract Hematology

Efficacy of Frontline Treatments for Newly Diagnosed Transplant-Ineligible Multiple Myeloma, a Network Meta-Analysis

Maggie Wong, Chen Wang, Cinnie Yentia Soekojo, Hung Chew Wong, Sanjay De Mel, Melissa Ooi, Miny Samuel, Yu Yang Soon, Wee Joo Chng

BLOOD (2022)

Letter Medicine, General & Internal

Non-infectious gastrointestinal manifestations of Good syndrome

Chen Wang, Yiyun Shi

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2023)

Review Oncology

Therapeutic approaches for the management of higher risk myelodysplastic syndromes

Chen Wang, David A. Sallman

Summary: The heterogeneous nature of myelodysplastic syndromes requires a risk-adapted therapeutic approach, especially for higher risk MDS. Mutational data can help refine the risk assessment. The principal therapeutic goal is to prolong survival and modify the natural history.

LEUKEMIA & LYMPHOMA (2023)

Editorial Material Endocrinology & Metabolism

Editorial: Monoclonal gammopathies of clinical significance: Clinical and therapeutic implications

Chen Wang, Chuanhui Xu, Jian Li

FRONTIERS IN ENDOCRINOLOGY (2023)

Review Oncology

Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes

Chen Wang, David. A. A. Sallman

Summary: Lower risk myelodysplastic syndromes have a low risk of transformation into acute myeloid leukemia and are characterized by an indolent disease course. The revised International Prognostic Scoring System is used to identify these patients, with future use of its molecular version expected to change treatment strategies. Symptomatic control is the main goal of care, with anemia being the most common indication for disease-specific therapies. Erythropoiesis-stimulating agents and lenalidomide monotherapy are the standard upfront treatments, with other therapeutic options available after treatment failure.

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2023)

No Data Available